Market Overview

Castle Biosciences to Present at the Baird 2018 Global Healthcare Conference


Castle Biosciences, Inc., the skin cancer diagnostics company providing
molecular diagnostics to improve cancer management decisions, today
announced that Derek Maetzold, President and CEO, will present at the
Baird Global Healthcare Conference on Wednesday, September 5th,
2018 at 11:25 a.m. ET in New York City.

About Castle Biosciences

Castle Biosciences is a molecular diagnostics company dedicated to
helping patients and their physicians make the best possible decisions
about their treatment and follow up care based on the individual
molecular signature of their tumor. The Company currently offers tests
for patients with cutaneous melanoma (DecisionDx®-Melanoma,
and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME
and DecisionDx®-UMSeq;,
with development programs in other underserved cancers. Castle
Biosciences is based in Friendswood, Texas (Houston), and has laboratory
operations in Phoenix, Arizona. More information can be found at

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are the trademarks of
Castle Biosciences, Inc. Any other trademarks are the property of their
respective owners.

View Comments and Join the Discussion!